RT Journal Article
SR Electronic
T1 Post-COVID conditions during Delta and early-Omicron SARS-CoV-2 variant periods among adults in the United States
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.08.09.23293776
DO 10.1101/2023.08.09.23293776
A1 Edwards, Deja
A1 Logan, Pamela
A1 Feldstein, Leora R.
A1 Fairlie, Tarayn
A1 Accorsi, Emma
A1 Saydah, Sharon
YR 2023
UL http://medrxiv.org/content/early/2023/08/13/2023.08.09.23293776.abstract
AB Background Post-COVID conditions after infection with new SARS-CoV-2 variants have been incompletely described. We compared the prevalence and risk factors for ongoing symptoms lasting 4 weeks or longer (often referred to as post-COVID Conditions) among adults who had tested positive vs. negative during the Delta and early-Omicron periods.Methods Self-reported survey data regarding symptoms and previous SARS-CoV 2 test results were collected from May 31 – July 6, 2022, from a probability sampling of United States adults. Respondents were classified according to their test result, predominant circulating variant when respondents first tested positive (Delta vs early-Omicron), and demographic risk factors.Results Among 2,421 respondents, 256 tested positive during Delta, 460 during early-Omicron, and 1,705 always tested negative. Nearly one-fourth (22.3%) of negative respondents reported ≥1symptom that lasted ≥4 weeks, compared to 60.6% (p<0.05) of respondents who tested positive during the Delta period and 47.8% (p<0.05) during the early-Omicron period. Fatigue, change in smell/taste, and cough were commonly reported by respondents who tested positive. Demographic risk factors associated with ongoing symptoms were being female and unemployed (aOR 1.28, 95% CI 1.06–1.55; aOR 1.48, 95% CI: 1.17–1.87).Conclusion The reported occurrence of ongoing symptoms associated with post-COVID conditions was reduced during the early-Omicron period, compared with Delta.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of the Centers for Disease Control and Prevention (CDC) gave ethical apporval for this work. While Porter Novelli Public Services and its vendors are not subject to CDC Human Subject Review, they adhere to all professional standards and codes of conduct set forth by the Council of American Survey Research Organizations (CASRO).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data underlying this study were provided by Porter Novelli Public Services under the terms of a research agreement. Inquiries regarding access to the data should be made directly to Porter Novelli.